Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori
Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the eff...
Saved in:
| Published in | Respiratory research Vol. 18; no. 1; pp. 109 - 9 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
30.05.2017
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the effects of AZ in COPD patients.
Plasma samples from 1018 subjects with COPD who participated in the Macrolide Azithromycin (MACRO) in COPD Study were used to determine the HP infection status at baseline and 12 months of follow-up using a serologic assay. Based on HP infection status and randomization to either AZ or placebo (PL), the subjects were divided into 4 groups: HP+/AZ, HP-/AZ, HP+/PL, and HP-/PL. Time to first exacerbation was compared across the 4 groups using Kaplan-Meier survival analysis and a Cox proportional hazards model. The rates of exacerbation were compared using both the Kruskal-Wallis test and negative binomial analysis. Blood biomarkers at enrolment and at follow-up visits 3, 12, and 13 (1 month after treatment was stopped) months were measured.
One hundred eighty one (17.8%) patients were seropositive to HP. Non-Caucasian participants were nearly three times more likely to be HP seropositive than Caucasian participants (37.4% vs 13.6%; p < 0.001). The median time to first exacerbation was significantly different across the four groups (p = 0.001) with the longest time in the HP+/AZ group (11.2 months, 95% CI; 8.4-12.5+) followed by the HP-/AZ group (8.0 months, 95% CI; 6.7-9.7). Hazard ratio (HR) for exacerbations was lowest in the HP+/AZ group after adjustment for age, sex, smoking status, ethnicity, history of peptic ulcer, dyspnea, previous hospital admission, GOLD grade of severity, and forced vital capacity (HR, 0.612; 95% CI, 0.442-0.846 vs HR, 0.789; 95% CI, 0.663-0.938 in the HP-/AZ group). Circulating levels of soluble tumor necrosis factor receptor-75 were reduced only in the HP+/AZ group after 3 months of AZ treatment (-0.87 ± 0.31 μg/L; p = 0.002); levels returned to baseline after discontinuing AZ.
AZ is effective in preventing COPD exacerbations in patients with HP seropositivity, possibly by modulating TNF pathways related to HP infection. |
|---|---|
| AbstractList | Background Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the effects of AZ in COPD patients. Methods Plasma samples from 1018 subjects with COPD who participated in the Macrolide Azithromycin (MACRO) in COPD Study were used to determine the HP infection status at baseline and 12 months of follow-up using a serologic assay. Based on HP infection status and randomization to either AZ or placebo (PL), the subjects were divided into 4 groups: HP+/AZ, HP-/AZ, HP+/PL, and HP-/PL. Time to first exacerbation was compared across the 4 groups using Kaplan-Meier survival analysis and a Cox proportional hazards model. The rates of exacerbation were compared using both the Kruskal-Wallis test and negative binomial analysis. Blood biomarkers at enrolment and at follow-up visits 3, 12, and 13 (1 month after treatment was stopped) months were measured. Results One hundred eighty one (17.8%) patients were seropositive to HP. Non-Caucasian participants were nearly three times more likely to be HP seropositive than Caucasian participants (37.4% vs 13.6%; p < 0.001). The median time to first exacerbation was significantly different across the four groups (p = 0.001) with the longest time in the HP+/AZ group (11.2 months, 95% CI; 8.4-12.5+) followed by the HP-/AZ group (8.0 months, 95% CI; 6.7-9.7). Hazard ratio (HR) for exacerbations was lowest in the HP+/AZ group after adjustment for age, sex, smoking status, ethnicity, history of peptic ulcer, dyspnea, previous hospital admission, GOLD grade of severity, and forced vital capacity (HR, 0.612; 95% CI, 0.442-0.846 vs HR, 0.789; 95% CI, 0.663-0.938 in the HP-/AZ group). Circulating levels of soluble tumor necrosis factor receptor-75 were reduced only in the HP+/AZ group after 3 months of AZ treatment (−0.87 ± 0.31 μg/L; p = 0.002); levels returned to baseline after discontinuing AZ. Conclusions AZ is effective in preventing COPD exacerbations in patients with HP seropositivity, possibly by modulating TNF pathways related to HP infection. Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the effects of AZ in COPD patients. Plasma samples from 1018 subjects with COPD who participated in the Macrolide Azithromycin (MACRO) in COPD Study were used to determine the HP infection status at baseline and 12 months of follow-up using a serologic assay. Based on HP infection status and randomization to either AZ or placebo (PL), the subjects were divided into 4 groups: HP+/AZ, HP-/AZ, HP+/PL, and HP-/PL. Time to first exacerbation was compared across the 4 groups using Kaplan-Meier survival analysis and a Cox proportional hazards model. The rates of exacerbation were compared using both the Kruskal-Wallis test and negative binomial analysis. Blood biomarkers at enrolment and at follow-up visits 3, 12, and 13 (1 month after treatment was stopped) months were measured. One hundred eighty one (17.8%) patients were seropositive to HP. Non-Caucasian participants were nearly three times more likely to be HP seropositive than Caucasian participants (37.4% vs 13.6%; p < 0.001). The median time to first exacerbation was significantly different across the four groups (p = 0.001) with the longest time in the HP+/AZ group (11.2 months, 95% CI; 8.4-12.5+) followed by the HP-/AZ group (8.0 months, 95% CI; 6.7-9.7). Hazard ratio (HR) for exacerbations was lowest in the HP+/AZ group after adjustment for age, sex, smoking status, ethnicity, history of peptic ulcer, dyspnea, previous hospital admission, GOLD grade of severity, and forced vital capacity (HR, 0.612; 95% CI, 0.442-0.846 vs HR, 0.789; 95% CI, 0.663-0.938 in the HP-/AZ group). Circulating levels of soluble tumor necrosis factor receptor-75 were reduced only in the HP+/AZ group after 3 months of AZ treatment (-0.87 ± 0.31 μg/L; p = 0.002); levels returned to baseline after discontinuing AZ. AZ is effective in preventing COPD exacerbations in patients with HP seropositivity, possibly by modulating TNF pathways related to HP infection. Abstract Background Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the effects of AZ in COPD patients. Methods Plasma samples from 1018 subjects with COPD who participated in the Macrolide Azithromycin (MACRO) in COPD Study were used to determine the HP infection status at baseline and 12 months of follow-up using a serologic assay. Based on HP infection status and randomization to either AZ or placebo (PL), the subjects were divided into 4 groups: HP+/AZ, HP-/AZ, HP+/PL, and HP-/PL. Time to first exacerbation was compared across the 4 groups using Kaplan-Meier survival analysis and a Cox proportional hazards model. The rates of exacerbation were compared using both the Kruskal-Wallis test and negative binomial analysis. Blood biomarkers at enrolment and at follow-up visits 3, 12, and 13 (1 month after treatment was stopped) months were measured. Results One hundred eighty one (17.8%) patients were seropositive to HP. Non-Caucasian participants were nearly three times more likely to be HP seropositive than Caucasian participants (37.4% vs 13.6%; p < 0.001). The median time to first exacerbation was significantly different across the four groups (p = 0.001) with the longest time in the HP+/AZ group (11.2 months, 95% CI; 8.4–12.5+) followed by the HP-/AZ group (8.0 months, 95% CI; 6.7–9.7). Hazard ratio (HR) for exacerbations was lowest in the HP+/AZ group after adjustment for age, sex, smoking status, ethnicity, history of peptic ulcer, dyspnea, previous hospital admission, GOLD grade of severity, and forced vital capacity (HR, 0.612; 95% CI, 0.442–0.846 vs HR, 0.789; 95% CI, 0.663–0.938 in the HP-/AZ group). Circulating levels of soluble tumor necrosis factor receptor-75 were reduced only in the HP+/AZ group after 3 months of AZ treatment (−0.87 ± 0.31 μg/L; p = 0.002); levels returned to baseline after discontinuing AZ. Conclusions AZ is effective in preventing COPD exacerbations in patients with HP seropositivity, possibly by modulating TNF pathways related to HP infection. Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the effects of AZ in COPD patients. Plasma samples from 1018 subjects with COPD who participated in the Macrolide Azithromycin (MACRO) in COPD Study were used to determine the HP infection status at baseline and 12 months of follow-up using a serologic assay. Based on HP infection status and randomization to either AZ or placebo (PL), the subjects were divided into 4 groups: HP+/AZ, HP-/AZ, HP+/PL, and HP-/PL. Time to first exacerbation was compared across the 4 groups using Kaplan-Meier survival analysis and a Cox proportional hazards model. The rates of exacerbation were compared using both the Kruskal-Wallis test and negative binomial analysis. Blood biomarkers at enrolment and at follow-up visits 3, 12, and 13 (1 month after treatment was stopped) months were measured. One hundred eighty one (17.8%) patients were seropositive to HP. Non-Caucasian participants were nearly three times more likely to be HP seropositive than Caucasian participants (37.4% vs 13.6%; p < 0.001). The median time to first exacerbation was significantly different across the four groups (p = 0.001) with the longest time in the HP+/AZ group (11.2 months, 95% CI; 8.4-12.5+) followed by the HP-/AZ group (8.0 months, 95% CI; 6.7-9.7). Hazard ratio (HR) for exacerbations was lowest in the HP+/AZ group after adjustment for age, sex, smoking status, ethnicity, history of peptic ulcer, dyspnea, previous hospital admission, GOLD grade of severity, and forced vital capacity (HR, 0.612; 95% CI, 0.442-0.846 vs HR, 0.789; 95% CI, 0.663-0.938 in the HP-/AZ group). Circulating levels of soluble tumor necrosis factor receptor-75 were reduced only in the HP+/AZ group after 3 months of AZ treatment (-0.87 [+ or -] 0.31 [mu]g/L; p = 0.002); levels returned to baseline after discontinuing AZ. AZ is effective in preventing COPD exacerbations in patients with HP seropositivity, possibly by modulating TNF pathways related to HP infection. Background Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the effects of AZ in COPD patients. Methods Plasma samples from 1018 subjects with COPD who participated in the Macrolide Azithromycin (MACRO) in COPD Study were used to determine the HP infection status at baseline and 12 months of follow-up using a serologic assay. Based on HP infection status and randomization to either AZ or placebo (PL), the subjects were divided into 4 groups: HP+/AZ, HP-/AZ, HP+/PL, and HP-/PL. Time to first exacerbation was compared across the 4 groups using Kaplan-Meier survival analysis and a Cox proportional hazards model. The rates of exacerbation were compared using both the Kruskal-Wallis test and negative binomial analysis. Blood biomarkers at enrolment and at follow-up visits 3, 12, and 13 (1 month after treatment was stopped) months were measured. Results One hundred eighty one (17.8%) patients were seropositive to HP. Non-Caucasian participants were nearly three times more likely to be HP seropositive than Caucasian participants (37.4% vs 13.6%; p < 0.001). The median time to first exacerbation was significantly different across the four groups (p = 0.001) with the longest time in the HP+/AZ group (11.2 months, 95% CI; 8.4-12.5+) followed by the HP-/AZ group (8.0 months, 95% CI; 6.7-9.7). Hazard ratio (HR) for exacerbations was lowest in the HP+/AZ group after adjustment for age, sex, smoking status, ethnicity, history of peptic ulcer, dyspnea, previous hospital admission, GOLD grade of severity, and forced vital capacity (HR, 0.612; 95% CI, 0.442-0.846 vs HR, 0.789; 95% CI, 0.663-0.938 in the HP-/AZ group). Circulating levels of soluble tumor necrosis factor receptor-75 were reduced only in the HP+/AZ group after 3 months of AZ treatment (-0.87 [+ or -] 0.31 [mu]g/L; p = 0.002); levels returned to baseline after discontinuing AZ. Conclusions AZ is effective in preventing COPD exacerbations in patients with HP seropositivity, possibly by modulating TNF pathways related to HP infection. Keywords: Helicobacter pylori, COPD, Exacerbation, Azithromycin Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the effects of AZ in COPD patients.BACKGROUNDHelicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the effects of AZ in COPD patients.Plasma samples from 1018 subjects with COPD who participated in the Macrolide Azithromycin (MACRO) in COPD Study were used to determine the HP infection status at baseline and 12 months of follow-up using a serologic assay. Based on HP infection status and randomization to either AZ or placebo (PL), the subjects were divided into 4 groups: HP+/AZ, HP-/AZ, HP+/PL, and HP-/PL. Time to first exacerbation was compared across the 4 groups using Kaplan-Meier survival analysis and a Cox proportional hazards model. The rates of exacerbation were compared using both the Kruskal-Wallis test and negative binomial analysis. Blood biomarkers at enrolment and at follow-up visits 3, 12, and 13 (1 month after treatment was stopped) months were measured.METHODSPlasma samples from 1018 subjects with COPD who participated in the Macrolide Azithromycin (MACRO) in COPD Study were used to determine the HP infection status at baseline and 12 months of follow-up using a serologic assay. Based on HP infection status and randomization to either AZ or placebo (PL), the subjects were divided into 4 groups: HP+/AZ, HP-/AZ, HP+/PL, and HP-/PL. Time to first exacerbation was compared across the 4 groups using Kaplan-Meier survival analysis and a Cox proportional hazards model. The rates of exacerbation were compared using both the Kruskal-Wallis test and negative binomial analysis. Blood biomarkers at enrolment and at follow-up visits 3, 12, and 13 (1 month after treatment was stopped) months were measured.One hundred eighty one (17.8%) patients were seropositive to HP. Non-Caucasian participants were nearly three times more likely to be HP seropositive than Caucasian participants (37.4% vs 13.6%; p < 0.001). The median time to first exacerbation was significantly different across the four groups (p = 0.001) with the longest time in the HP+/AZ group (11.2 months, 95% CI; 8.4-12.5+) followed by the HP-/AZ group (8.0 months, 95% CI; 6.7-9.7). Hazard ratio (HR) for exacerbations was lowest in the HP+/AZ group after adjustment for age, sex, smoking status, ethnicity, history of peptic ulcer, dyspnea, previous hospital admission, GOLD grade of severity, and forced vital capacity (HR, 0.612; 95% CI, 0.442-0.846 vs HR, 0.789; 95% CI, 0.663-0.938 in the HP-/AZ group). Circulating levels of soluble tumor necrosis factor receptor-75 were reduced only in the HP+/AZ group after 3 months of AZ treatment (-0.87 ± 0.31 μg/L; p = 0.002); levels returned to baseline after discontinuing AZ.RESULTSOne hundred eighty one (17.8%) patients were seropositive to HP. Non-Caucasian participants were nearly three times more likely to be HP seropositive than Caucasian participants (37.4% vs 13.6%; p < 0.001). The median time to first exacerbation was significantly different across the four groups (p = 0.001) with the longest time in the HP+/AZ group (11.2 months, 95% CI; 8.4-12.5+) followed by the HP-/AZ group (8.0 months, 95% CI; 6.7-9.7). Hazard ratio (HR) for exacerbations was lowest in the HP+/AZ group after adjustment for age, sex, smoking status, ethnicity, history of peptic ulcer, dyspnea, previous hospital admission, GOLD grade of severity, and forced vital capacity (HR, 0.612; 95% CI, 0.442-0.846 vs HR, 0.789; 95% CI, 0.663-0.938 in the HP-/AZ group). Circulating levels of soluble tumor necrosis factor receptor-75 were reduced only in the HP+/AZ group after 3 months of AZ treatment (-0.87 ± 0.31 μg/L; p = 0.002); levels returned to baseline after discontinuing AZ.AZ is effective in preventing COPD exacerbations in patients with HP seropositivity, possibly by modulating TNF pathways related to HP infection.CONCLUSIONSAZ is effective in preventing COPD exacerbations in patients with HP seropositivity, possibly by modulating TNF pathways related to HP infection. |
| ArticleNumber | 109 |
| Audience | Academic |
| Author | Lee, Eun Chong Criner, Gerard J. Connett, John E. Sze, Marc A. Martinez, Fernando J. Aaron, Shawn D. Albert, Richard Lazarus, Stephen C. Fishbane, Nick Woodruff, Prescott G. Oh, Yeni Sin, Don D. Tam, Sheena Han, Meilan K. Reed, Robert M. Man, S. F. Paul Ra, Seung Won |
| Author_xml | – sequence: 1 givenname: Seung Won surname: Ra fullname: Ra, Seung Won – sequence: 2 givenname: Marc A. surname: Sze fullname: Sze, Marc A. – sequence: 3 givenname: Eun Chong surname: Lee fullname: Lee, Eun Chong – sequence: 4 givenname: Sheena surname: Tam fullname: Tam, Sheena – sequence: 5 givenname: Yeni surname: Oh fullname: Oh, Yeni – sequence: 6 givenname: Nick surname: Fishbane fullname: Fishbane, Nick – sequence: 7 givenname: Gerard J. surname: Criner fullname: Criner, Gerard J. – sequence: 8 givenname: Prescott G. surname: Woodruff fullname: Woodruff, Prescott G. – sequence: 9 givenname: Stephen C. surname: Lazarus fullname: Lazarus, Stephen C. – sequence: 10 givenname: Richard surname: Albert fullname: Albert, Richard – sequence: 11 givenname: John E. surname: Connett fullname: Connett, John E. – sequence: 12 givenname: Meilan K. surname: Han fullname: Han, Meilan K. – sequence: 13 givenname: Fernando J. surname: Martinez fullname: Martinez, Fernando J. – sequence: 14 givenname: Shawn D. surname: Aaron fullname: Aaron, Shawn D. – sequence: 15 givenname: Robert M. surname: Reed fullname: Reed, Robert M. – sequence: 16 givenname: S. F. Paul surname: Man fullname: Man, S. F. Paul – sequence: 17 givenname: Don D. surname: Sin fullname: Sin, Don D. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28558695$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1uEzEUhS1URNvAA7BBI7FhM8We8c94gxSFllaqVBYgsUCyPJ7r1GFiB3sGEp4eJymlqRDywlf2d4597XOKjnzwgNBLgs8IafjbRCpZkxITUWImabl-gk4I5ayUsv5y9KA-RqcpLXAGG8GeoeOqYazhkp2gr9NfbriNYbkxzhfad0V06VsRbDG7-fi-gLU2EFs9uOBTkYlVLsEPqfiZZTt-W4RxKC6hdya02gwQi9WmD9E9R0-t7hO8uJsn6PPF-afZZXl98-FqNr0uDeN4KEFYaduKtrLDBIPlpuGE6Jq2RjLWMqy7rhWWQKMbXjUgKyFqDVZj3hjo2nqCrva-XdALtYpuqeNGBe3UbiHEudJxcKYHxRgTrelMV2tBrbBaVgQolXVlsN17vdt7rcZ2CZ3JzUbdH5ge7nh3q-bhh2KUYZwvNkFv7gxi-D5CGtTSJQN9rz2EMSkiMa1qiTnJ6OtH6CKM0een2lK8pg3h7C8117kB523I55qtqZoyQmosMKWZOvsHlUcHy_wvHqzL6weCVw8bve_wTzYyQPaAiSGlCPYeIVht86f2-VM5VmqbP7XOGvFIY9ywS0--jev_o_wNmqff-w |
| CitedBy_id | crossref_primary_10_1016_j_rceng_2024_12_004 crossref_primary_10_1111_all_14768 crossref_primary_10_1016_j_rce_2024_12_002 crossref_primary_10_1159_000538911 crossref_primary_10_1111_1440_1681_13062 |
| Cites_doi | 10.1136/gutjnl-2012-302084 10.1093/jac/dkn007 10.1183/09031936.00140613 10.1016/S0924-8579(98)00091-0 10.1371/journal.pone.0111228 10.1136/thoraxjnl-2015-207059 10.3748/wjg.15.6102 10.1165/rcmb.2015-0250PS 10.1172/JCI20925 10.1056/NEJMoa1104623 10.1086/515376 10.1007/978-1-4899-4541-9 10.1183/09031936.01.00229701 10.7150/ijbs.5.667 10.1016/0140-6736(93)91473-Y 10.7326/0003-4819-155-3-201108020-00008 10.1093/aje/kwr288 10.1016/0140-6736(92)90929-W 10.1016/S1473-3099(06)70627-2 10.1155/1998/303628 10.1136/jech.54.6.444 10.1081/IPH-100102563 10.1152/ajpgi.00422.2001 10.1016/0016-5085(92)91782-Y 10.1164/rccm.201402-0207OC 10.1513/AnnalsATS.201403-125OC 10.1080/00365540410021063 10.3109/00365548.2014.989539 10.1128/AAC.36.5.1133 10.1016/j.femsim.2004.10.013 10.1007/BF02962382 10.1371/journal.pone.0037483 10.1017/S0950268814003938 10.1111/hel.12043 10.1164/ajrccm.153.2.8564092 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2017 BioMed Central Ltd. Copyright BioMed Central 2017 The Author(s). 2017 |
| Copyright_xml | – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: Copyright BioMed Central 2017 – notice: The Author(s). 2017 |
| CorporateAuthor | on behalf of the Canadian Respiratory Research Network Canadian Respiratory Research Network |
| CorporateAuthor_xml | – name: on behalf of the Canadian Respiratory Research Network – name: Canadian Respiratory Research Network |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7U7 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12931-017-0594-x |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts Toxicology Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: WRHA-DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1465-993X |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_5557bcdcd3a74f7fa921e44932c0fedb PMC5450077 A511307044 28558695 10_1186_s12931_017_0594_x |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | Canada |
| GeographicLocations_xml | – name: Canada |
| GrantInformation_xml | – fundername: CIHR – fundername: NHLBI NIH HHS grantid: K24 HL137013 – fundername: ; – fundername: ; grantid: 10-03 |
| GroupedDBID | --- 0R~ 29P 2WC 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IPNFZ ITC KQ8 M1P M48 O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF FRP M~E NPM PMFND 7QL 7U7 7U9 7XB 8FK AHSBF AZQEC C1K DWQXO H94 K9. M7N PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c560t-e7f9fb24b9d010ef6c8611a34bc955b50addb7f1e8a8628e92773aefa068cedb3 |
| IEDL.DBID | DOA |
| ISSN | 1465-993X 1465-9921 |
| IngestDate | Wed Aug 27 01:30:05 EDT 2025 Thu Aug 21 14:32:02 EDT 2025 Fri Jul 11 05:25:15 EDT 2025 Sat Aug 23 14:58:17 EDT 2025 Tue Jun 17 21:13:30 EDT 2025 Tue Jun 10 20:40:27 EDT 2025 Wed Feb 19 02:43:36 EST 2025 Thu Apr 24 23:05:25 EDT 2025 Tue Jul 01 02:43:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Exacerbation Helicobacter pylori Azithromycin COPD |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c560t-e7f9fb24b9d010ef6c8611a34bc955b50addb7f1e8a8628e92773aefa068cedb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://doaj.org/article/5557bcdcd3a74f7fa921e44932c0fedb |
| PMID | 28558695 |
| PQID | 1906348165 |
| PQPubID | 42864 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_5557bcdcd3a74f7fa921e44932c0fedb pubmedcentral_primary_oai_pubmedcentral_nih_gov_5450077 proquest_miscellaneous_1904239061 proquest_journals_1906348165 gale_infotracmisc_A511307044 gale_infotracacademiconefile_A511307044 pubmed_primary_28558695 crossref_primary_10_1186_s12931_017_0594_x crossref_citationtrail_10_1186_s12931_017_0594_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-05-30 |
| PublicationDateYYYYMMDD | 2017-05-30 |
| PublicationDate_xml | – month: 05 year: 2017 text: 2017-05-30 day: 30 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Respiratory research |
| PublicationTitleAlternate | Respir Res |
| PublicationYear | 2017 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | TU Kosunen (594_CR16) 1992; 339 F Russo (594_CR38) 2001; 23 K Yamauchi (594_CR13) 2009; 5 AF Cutler (594_CR31) 1996; 91 PG Woodruff (594_CR18) 2014; 43 MA Sze (594_CR6) 2015; 70 MJ Blaser (594_CR8) 2004; 113 594_CR21 A Qaseem (594_CR20) 2011; 155 W Dohmen (594_CR33) 1998; 26 WS Krueger (594_CR28) 2015; 143 F Perri (594_CR37) 1999; 31 F Wang (594_CR5) 2015; 47 P Malfertheiner (594_CR35) 2012; 61 KF Chung (594_CR40) 2001; 34 YH Grad (594_CR23) 2012; 175 WM Wang (594_CR30) 1994; 89 A Agusti (594_CR1) 2012; 7 VG Loo (594_CR10) 1992; 36 MA Sze (594_CR3) 2014; 9 RP Young (594_CR4) 2016; 54 I Daugule (594_CR32) 2005; 37 T Kumagai (594_CR27) 1998; 178 MM Gerrits (594_CR34) 2006; 6 BS Murphy (594_CR12) 2008; 61 MK Han (594_CR22) 2014; 189 SI Rennard (594_CR2) 2015; 12 VM Keatings (594_CR39) 1996; 153 B Efron (594_CR19) 1993 J Parsonnet (594_CR26) 1992; 102 FS Lehmann (594_CR7) 2002; 283 RM Peek Jr (594_CR36) 1995; 73 EJ Kuipers (594_CR25) 1993; 342 MM D’Elios (594_CR9) 2005; 44 RK Albert (594_CR15) 2011; 365 AA Khan (594_CR14) 1999; 11 JH Jung (594_CR29) 2013; 18 CA Fallone (594_CR17) 1998; 12 J Dong (594_CR11) 2009; 15 S Rosenstock (594_CR24) 2000; 54 22085628 - Am J Epidemiol. 2012 Jan 1;175(1):54-9 22491499 - Gut. 2012 May;61(5):646-64 7942669 - Am J Gastroenterol. 1994 Oct;89(10):1793-6 14755326 - J Clin Invest. 2004 Feb;113(3):321-33 24136332 - Eur Respir J. 2014 Jan;43(1):295-8 10818120 - J Epidemiol Community Health. 2000 Jun;54(6):444-50 9559206 - Can J Gastroenterol. 1998 Mar;12(2):117-24 25642832 - Ann Am Thorac Soc. 2015 Mar;12(3):303-12 9867486 - Infection. 1998 Jul-Aug;26(4):256-62 11322645 - Immunopharmacol Immunotoxicol. 2001 Feb;23(1):13-24 8101585 - Lancet. 1993 Aug 7;342(8867):328-31 12121897 - Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G481-8 18230686 - J Antimicrob Chemother. 2008 Mar;61(3):554-60 26024688 - Thorax. 2015 Oct;70(10):923-9 8561150 - Am J Gastroenterol. 1996 Jan;91(1):85-8 25592266 - Epidemiol Infect. 2015 Sep;143(12):2520-31 15866204 - FEMS Immunol Med Microbiol. 2005 May 1;44(2):113-9 1348298 - Lancet. 1992 Apr 11;339(8798):893-5 17067919 - Lancet Infect Dis. 2006 Nov;6(11):699-709 24779680 - Am J Respir Crit Care Med. 2014 Jun 15;189(12):1503-8 10425573 - Ital J Gastroenterol Hepatol. 1999 May;31(4):290-4 21810710 - Ann Intern Med. 2011 Aug 2;155(3):179-91 26473323 - Am J Respir Cell Mol Biol. 2016 Feb;54(2):161-9 8564092 - Am J Respir Crit Care Med. 1996 Feb;153(2):530-4 1727779 - Gastroenterology. 1992 Jan;102(1):41-6 16051567 - Scand J Infect Dis. 2005;37(5):326-9 12392035 - Eur Respir J Suppl. 2001 Dec;34:50s-59s 19893639 - Int J Biol Sci. 2009 Oct 23;5(7):667-78 25333938 - PLoS One. 2014 Oct 21;9(10):e111228 21864166 - N Engl J Med. 2011 Aug 25;365(8):689-98 9728540 - J Infect Dis. 1998 Sep;178(3):717-21 25797276 - Infect Dis (Lond). 2015 Sep;47(9):597-603 20027685 - World J Gastroenterol. 2009 Dec 28;15(48):6102-10 10221415 - Int J Antimicrob Agents. 1999 Feb;11(2):121-32 1510406 - Antimicrob Agents Chemother. 1992 May;36(5):1133-5 8558837 - Lab Invest. 1995 Dec;73(6):760-70 23521610 - Helicobacter. 2013 Aug;18(4):299-308 22624038 - PLoS One. 2012;7(5):e37483 |
| References_xml | – volume: 61 start-page: 646 year: 2012 ident: 594_CR35 publication-title: Gut doi: 10.1136/gutjnl-2012-302084 – volume: 61 start-page: 554 year: 2008 ident: 594_CR12 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkn007 – volume: 43 start-page: 295 year: 2014 ident: 594_CR18 publication-title: Eur Respir J doi: 10.1183/09031936.00140613 – volume: 11 start-page: 121 year: 1999 ident: 594_CR14 publication-title: Int J Antimicrob Agents doi: 10.1016/S0924-8579(98)00091-0 – volume: 9 start-page: e111228 year: 2014 ident: 594_CR3 publication-title: PLoS One doi: 10.1371/journal.pone.0111228 – volume: 70 start-page: 923 year: 2015 ident: 594_CR6 publication-title: Thorax doi: 10.1136/thoraxjnl-2015-207059 – volume: 15 start-page: 6102 year: 2009 ident: 594_CR11 publication-title: World J Gastroenterol doi: 10.3748/wjg.15.6102 – volume: 54 start-page: 161 year: 2016 ident: 594_CR4 publication-title: Am J Respir Cell Mol Biol doi: 10.1165/rcmb.2015-0250PS – volume: 113 start-page: 321 year: 2004 ident: 594_CR8 publication-title: J Clin Invest doi: 10.1172/JCI20925 – volume: 365 start-page: 689 year: 2011 ident: 594_CR15 publication-title: N Engl J Med doi: 10.1056/NEJMoa1104623 – volume: 178 start-page: 717 year: 1998 ident: 594_CR27 publication-title: J Infect Dis doi: 10.1086/515376 – volume-title: An introduction to the bootstrap year: 1993 ident: 594_CR19 doi: 10.1007/978-1-4899-4541-9 – volume: 31 start-page: 290 year: 1999 ident: 594_CR37 publication-title: Ital J Gastroenterol Hepatol – volume: 34 start-page: 50s year: 2001 ident: 594_CR40 publication-title: Eur Respir J Suppl doi: 10.1183/09031936.01.00229701 – volume: 5 start-page: 667 year: 2009 ident: 594_CR13 publication-title: Int J Biol Sci doi: 10.7150/ijbs.5.667 – volume: 342 start-page: 328 year: 1993 ident: 594_CR25 publication-title: Lancet doi: 10.1016/0140-6736(93)91473-Y – volume: 155 start-page: 179 year: 2011 ident: 594_CR20 publication-title: Ann Intern Med doi: 10.7326/0003-4819-155-3-201108020-00008 – volume: 175 start-page: 54 year: 2012 ident: 594_CR23 publication-title: Am J Epidemiol doi: 10.1093/aje/kwr288 – volume: 89 start-page: 1793 year: 1994 ident: 594_CR30 publication-title: Am J Gastroenterol – volume: 339 start-page: 893 year: 1992 ident: 594_CR16 publication-title: Lancet doi: 10.1016/0140-6736(92)90929-W – volume: 6 start-page: 699 year: 2006 ident: 594_CR34 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(06)70627-2 – volume: 12 start-page: 117 year: 1998 ident: 594_CR17 publication-title: Can J Gastroenterol doi: 10.1155/1998/303628 – volume: 54 start-page: 444 year: 2000 ident: 594_CR24 publication-title: J Epidemiol Community Health doi: 10.1136/jech.54.6.444 – volume: 23 start-page: 13 year: 2001 ident: 594_CR38 publication-title: Immunopharmacol Immunotoxicol doi: 10.1081/IPH-100102563 – volume: 283 start-page: G481 year: 2002 ident: 594_CR7 publication-title: Am J Physiol Gastrointest Liver Physiol doi: 10.1152/ajpgi.00422.2001 – ident: 594_CR21 – volume: 102 start-page: 41 year: 1992 ident: 594_CR26 publication-title: Gastroenterology doi: 10.1016/0016-5085(92)91782-Y – volume: 91 start-page: 85 year: 1996 ident: 594_CR31 publication-title: Am J Gastroenterol – volume: 189 start-page: 1503 year: 2014 ident: 594_CR22 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201402-0207OC – volume: 12 start-page: 303 year: 2015 ident: 594_CR2 publication-title: Ann Am Thorac Soc doi: 10.1513/AnnalsATS.201403-125OC – volume: 37 start-page: 326 year: 2005 ident: 594_CR32 publication-title: Scand J Infect Dis doi: 10.1080/00365540410021063 – volume: 47 start-page: 597 year: 2015 ident: 594_CR5 publication-title: Infect Dis (Lond) doi: 10.3109/00365548.2014.989539 – volume: 36 start-page: 1133 year: 1992 ident: 594_CR10 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.36.5.1133 – volume: 44 start-page: 113 year: 2005 ident: 594_CR9 publication-title: FEMS Immunol Med Microbiol doi: 10.1016/j.femsim.2004.10.013 – volume: 26 start-page: 256 year: 1998 ident: 594_CR33 publication-title: Infection doi: 10.1007/BF02962382 – volume: 73 start-page: 760 year: 1995 ident: 594_CR36 publication-title: Lab Invest – volume: 7 start-page: e37483 year: 2012 ident: 594_CR1 publication-title: PLoS One doi: 10.1371/journal.pone.0037483 – volume: 143 start-page: 2520 year: 2015 ident: 594_CR28 publication-title: Epidemiol Infect doi: 10.1017/S0950268814003938 – volume: 18 start-page: 299 year: 2013 ident: 594_CR29 publication-title: Helicobacter doi: 10.1111/hel.12043 – volume: 153 start-page: 530 year: 1996 ident: 594_CR39 publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.153.2.8564092 – reference: 25797276 - Infect Dis (Lond). 2015 Sep;47(9):597-603 – reference: 17067919 - Lancet Infect Dis. 2006 Nov;6(11):699-709 – reference: 26024688 - Thorax. 2015 Oct;70(10):923-9 – reference: 1510406 - Antimicrob Agents Chemother. 1992 May;36(5):1133-5 – reference: 20027685 - World J Gastroenterol. 2009 Dec 28;15(48):6102-10 – reference: 24136332 - Eur Respir J. 2014 Jan;43(1):295-8 – reference: 7942669 - Am J Gastroenterol. 1994 Oct;89(10):1793-6 – reference: 9867486 - Infection. 1998 Jul-Aug;26(4):256-62 – reference: 11322645 - Immunopharmacol Immunotoxicol. 2001 Feb;23(1):13-24 – reference: 19893639 - Int J Biol Sci. 2009 Oct 23;5(7):667-78 – reference: 10425573 - Ital J Gastroenterol Hepatol. 1999 May;31(4):290-4 – reference: 21864166 - N Engl J Med. 2011 Aug 25;365(8):689-98 – reference: 22085628 - Am J Epidemiol. 2012 Jan 1;175(1):54-9 – reference: 9559206 - Can J Gastroenterol. 1998 Mar;12(2):117-24 – reference: 16051567 - Scand J Infect Dis. 2005;37(5):326-9 – reference: 8101585 - Lancet. 1993 Aug 7;342(8867):328-31 – reference: 22491499 - Gut. 2012 May;61(5):646-64 – reference: 8561150 - Am J Gastroenterol. 1996 Jan;91(1):85-8 – reference: 25642832 - Ann Am Thorac Soc. 2015 Mar;12(3):303-12 – reference: 15866204 - FEMS Immunol Med Microbiol. 2005 May 1;44(2):113-9 – reference: 10818120 - J Epidemiol Community Health. 2000 Jun;54(6):444-50 – reference: 8558837 - Lab Invest. 1995 Dec;73(6):760-70 – reference: 1727779 - Gastroenterology. 1992 Jan;102(1):41-6 – reference: 18230686 - J Antimicrob Chemother. 2008 Mar;61(3):554-60 – reference: 25592266 - Epidemiol Infect. 2015 Sep;143(12):2520-31 – reference: 12121897 - Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G481-8 – reference: 21810710 - Ann Intern Med. 2011 Aug 2;155(3):179-91 – reference: 25333938 - PLoS One. 2014 Oct 21;9(10):e111228 – reference: 9728540 - J Infect Dis. 1998 Sep;178(3):717-21 – reference: 1348298 - Lancet. 1992 Apr 11;339(8798):893-5 – reference: 22624038 - PLoS One. 2012;7(5):e37483 – reference: 26473323 - Am J Respir Cell Mol Biol. 2016 Feb;54(2):161-9 – reference: 8564092 - Am J Respir Crit Care Med. 1996 Feb;153(2):530-4 – reference: 10221415 - Int J Antimicrob Agents. 1999 Feb;11(2):121-32 – reference: 14755326 - J Clin Invest. 2004 Feb;113(3):321-33 – reference: 12392035 - Eur Respir J Suppl. 2001 Dec;34:50s-59s – reference: 24779680 - Am J Respir Crit Care Med. 2014 Jun 15;189(12):1503-8 – reference: 23521610 - Helicobacter. 2013 Aug;18(4):299-308 |
| SSID | ssj0017875 |
| Score | 2.1985266 |
| Snippet | Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients.... Background Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease... Abstract Background Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 109 |
| SubjectTerms | Age Aged Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Antibiotics Antibodies, Bacterial - blood Assaying Azithromycin Azithromycin - adverse effects Azithromycin - therapeutic use Biomarkers Biomarkers - blood Blood C-Reactive Protein - metabolism Care and treatment Chronic infection Chronic obstructive lung disease Chronic obstructive pulmonary disease Complications and side effects COPD Cytokines Disease Progression Disease-Free Survival Dosage and administration Drug therapy Dyspnea Exacerbation Female Hazards Health aspects Health hazards Health risk assessment Helicobacter infections Helicobacter Infections - blood Helicobacter Infections - diagnosis Helicobacter Infections - drug therapy Helicobacter Infections - microbiology Helicobacter pylori Helicobacter pylori - drug effects Helicobacter pylori - immunology Humans Infections Inflammation Kaplan-Meier Estimate Lung - drug effects Lung - microbiology Lung - physiopathology Lung diseases Male Middle Aged Minority & ethnic groups Obstructive lung disease Patients Plasma Prevention Prognosis Proportional Hazards Models Pulmonary Disease, Chronic Obstructive - diagnosis Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - microbiology Pulmonary Disease, Chronic Obstructive - physiopathology Quality Randomization Receptors, Tumor Necrosis Factor, Type II - blood Respiration Respiratory function Risk Factors Serologic Tests Sex Smoking Studies Survival Time Factors TNF inhibitors Treatment Outcome Tumor necrosis factor Tumor necrosis factor-TNF Ulcers |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA9aQXwRv7taJYIgCKH7kY_NUzmrpQhVHyzcgxCSbKIHdffs3cHpX9-Z3dzaRejb7mYCm8lkPpLJbwh5kweQHFs0TIM_wHgZCmZzK1jtdRUdj0pwvCh89lmenvNPczFPG26rlFa504m9om46j3vkh2C4JF4aleJo-Zth1Sg8XU0lNG6TOwhdhildaj4GXAUIoxhuFwmmdVmkU82ilocrtHMYSCuGiCVsO7FLPXz__0r6mpWaZlBeM0knD8j95EvS2TD5D8mt0D4id8_Saflj8n32d4FlEH79gXdq24ZiIjntIj3-8vUDDVvrganDlh0FioSxuqK4OdvT40O3WVMwTiAxrkd2pkuM8RdPyPnJx2_HpyxVU2AevJo1Cyrq6ErudAMxWIjS17IobMWd10I4kYOmcyoWobYQ5dRBl0pVNkSby9qHxlVPyV7btWGfUCvL3Idaat0obkNunbLeR8tt4cDDFBnJd7w0PkGNY8WLC9OHHLU0A_sNsN8g-802I-_GLssBZ-Mm4vc4QSMhQmT3H7rLHyatOCOEUM43vqmsApmLFgQgcA7-qs8jjCcjb3F6DS5k-Dlv030EGCJCYpkZuKKoEDnPyMGEEhagnzbvBMQkBbAy_8Q1I6_HZuyJSW1t6DY9DcIvgkeVkWeDPI1DKmshgMHQW00kbTLmaUu7-NnDg4NPjCBNz2_-rRfkXjlIP6vyA7K3vtyEl-Bfrd2rfhFdAf8HI6s priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA7LCuJFfNu6SgRBEKL9yKNzEBlXl0UY9eDAHoSQpJN1YO1e5wGz_nqr0j3jNi6evE1PKtCpVKW-6iRfEfI8D2A5tmiYBjzAeBkKZnMrWO11FR2PSnC8KDz9JI9n_OOJONkj2_JWgwKXV6Z2WE9qtjh7tfl58RYc_k1y-Fq-XmLMwqRYMWQfYQApr0FgUuinU_5nUwFsUwwbm1d2G4WmxOD_9zp9KVCND1FeikpHt8jNAU7SST__t8leaO-Q69Nhw_wu-Tb5NcdKCD8u4JnatqF4lpx2kR5-_vKeho31oNf-qx0FiYFmdUnx-2ySxx_dekUhPoHRuETuTM8xzZ_fI7OjD18Pj9lQUIF5ADYrFlTU0ZXc6QbSsBClr2VR2Io7r4VwIofFzqlYhNpColMHXSpV2RBtLmsfGlfdJ_tt14aHhFpZ5j7UUutGcRty65T1PlpuCwcgU2Qk3-rS-IFtHItenJmUddTS9Oo3oH6D6jebjLzcdTnvqTb-JfwOJ2gniCzZ6Y9ucWoGpzNCCOV845vKKjC7aHVZBM4Bsvo8wngy8gKn16B1wct5O1xJgCEiK5aZABrFNZHzjByMJMEH_bh5ayBma8IGoJbEa84SlPFs14w98VxbG7p1kkEGRgBVGXnQ29NuSGUtBCgYequRpY3GPG5p598TQzjAYuRpevQ_lPSY3Ch7H2FVfkD2V4t1eAJAbOWeJvf6DbrKMqM priority: 102 providerName: Scholars Portal |
| Title | Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28558695 https://www.proquest.com/docview/1906348165 https://www.proquest.com/docview/1904239061 https://pubmed.ncbi.nlm.nih.gov/PMC5450077 https://doaj.org/article/5557bcdcd3a74f7fa921e44932c0fedb |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bixMxFA66gvgi3p11LREEQQg7l9zmsbvushS6LupCH4SQZBIs6HSxLXT99Z4zk5YOgr740naaE5h8c5LznUnyhZC3eQDPsUXDauADjJehYDa3gmlfV9HxqATHjcLTS3lxzSczMds76gvXhPXywD1wx0II5Xzjm8oqqBptXRaBc6AdPo-hcTj6QszbJlNp_gDcUKQ5zELL4yVGNUybFUN9ErYZRKFOrP_PIXkvJg3XS-4FoPNH5GFijnTc3_Fjcie0T8j9aZobf0q-jn_N8dCDH7dwTW3bUFw2TheRnn68-kDDxnqAsH9BR8EiKaouKb6K7ezxx2K9ohCKwD9cp-NMbzCjnz8j1-dnX04vWDo7gXngMCsWVKyjK7mrG8i4QpRey6KwFXe-FsKJHMY1p2IRtIWcRoe6VKqyIdpcag-wVs_JQbtow0tCrSxzH7Ss60ZxG3LrlPU-Wm4LB3xSZCTfYml8EhbH8y2-my7B0NL08BuA3yD8ZpOR97sqN72qxt-MT_AB7QxRELv7A9zEJDcx_3KTjLzDx2uw28LNeZt2H0ATUQDLjIF44vDHeUaOBpbQ3fyweOsgJnX3pQFWJXFHswQw3uyKsSYuYWvDYt3ZoNgi8KeMvOj9adekUgsBAENtNfC0QZuHJe38WycGDgwYJZkO_wdIr8iDsu8jrMqPyMHq5zq8Bs61ciNyV83UiNwbjyefJ_B9cnZ59WnUdTr4nHL9G7jiMGg |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEviG8CA4wEQkKylg87Th4Q6r7UsbVMaJP2MMnYjg2VIClrKzr-KP5G7pK0LELa296a-hzF5zvfne37HSGvQweSo6OC5eAPMB67iOlQC5bZPPGGeyk4JgoPR-nghH88Fadr5M8yFwavVS7XxHqhLiqLe-SbYLhSTBpNxYfJT4ZVo_B0dVlCoxGLA3fxC0K26fv9HZjfN3G8t3u8PWBtVQFmwbrPmJM-9ybmJi8gFnE-tVkaRTrhxuZCGBGCxhvpI5dp8PYzl8dSJtp5HaaZdYVJ4L03yDpPIJTpkfWt3dHR59W5BYi_aPKZBMvzOGrPUaMs3ZyiZcXQXTLESGGLjiWsCwb8bxYu2cXunc1LRnDvLrnTeq-034jbPbLmyvvk5rA9n39Azvq_x1h44ccFPFNdFhSvrtPK0-1PRzvULbSFaWw2CSlQtKiuU4rbwTU9_qjmMwrmEGTU1FjSdIK7CuOH5ORaOP2I9MqqdE8I1WkcWpeleV5Irl2ojdTWes11ZMCnFQEJl7xUtgU3xxob31Ud5GSpativgP0K2a8WAXm36jJpkD2uIt7CCVoRIih3_Ud1_lW1Oq6EENLYwhaJliDlXoMAOM7BQ7ahh_EE5C1Or8KlAz7O6jYDAoaIIFyqD84vLsGcB2SjQwkqb7vNSwFR7ZIzVf8UJCCvVs3YE6_Rla6a1zQI-Ag-XEAeN_K0GlKcCQEMht6yI2mdMXdbyvG3GpAcvHCEhXp69We9JLcGx8NDdbg_OnhGbseNJrAk3CC92fncPQfvbmZetCpFyZfr1uK_KqZjng |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Azithromycin+and+risk+of+COPD+exacerbations+in+patients+with+and+without+Helicobacter+pylori&rft.jtitle=Respiratory+research&rft.au=Seung+Won+Ra&rft.au=Marc+A.+Sze&rft.au=Eun+Chong+Lee&rft.au=Sheena+Tam&rft.date=2017-05-30&rft.pub=BMC&rft.eissn=1465-993X&rft.volume=18&rft.issue=1&rft.spage=1&rft.epage=9&rft_id=info:doi/10.1186%2Fs12931-017-0594-x&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_5557bcdcd3a74f7fa921e44932c0fedb |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-993X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-993X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-993X&client=summon |